Investors focused on the Medical space have likely heard of Biogen (BIIB Quick QuoteBIIB - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Biogen is a member of our Medical group, which includes 758 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. BIIB is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for BIIB's full-year earnings has moved 6.34% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

Based on the most recent data, BIIB has returned 7.65% so far this year. At the same time, Medical stocks have gained an average of 5.14%. This shows that Biogen is outperforming its peers so far this year.

Breaking things down more, BIIB is a member of the Medical - Biomedical and Genetics industry, which includes 280 individual companies and currently sits at #103 in the Zacks Industry Rank. This group has lost an average of 2.42% so far this year, so BIIB is performing better in this area.

Investors with an interest in Medical stocks should continue to track BIIB. The stock will be looking to continue its solid performance.